TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7964957

Group type: EXPERIMENTAL
Intervention: Interferon alfa 3 MU three times weekly
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: IFN alfa 5 MU three times weekly plus DEX
Number of subjects: 522

Group type: COMPARATOR
Intervention: Higher dose-intensity glucocorticoids
Number of subjects: 522
Study: 3655306

Group type: EXPERIMENTAL
Intervention: Repeated paracentesis plus i.v. albumin infusion (n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Diuretics (n = 21)
Number of subjects: 41
Study: 29788137

Group type: EXPERIMENTAL
Intervention: TELE‐IBD EOW (every other week)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: TELE‐IBD W (weekly)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 219
Study: 27488380

Group type: EXPERIMENTAL
Intervention: Combined intermittent pneumatic compression (IPC) and pharmacologic prophylaxis
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Pharmacologic prophylaxis alone
Number of subjects: 2000
Study: 25173199

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 100
Study: 22519127

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone/salmeterol (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide/formoterol (group B)
Number of subjects: 30
Study: 20691689

Group type: EXPERIMENTAL
Intervention: 500 mg CDC
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1000 mg CDC
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18500596

Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endotracheal tube (ET)
Number of subjects: 50
Study: 16538529

Group type: EXPERIMENTAL
Intervention: Tamoxifen (Tam) 20 mg per day orally for 5 years
Number of subjects: 541

Group type: COMPARATOR
Intervention: Tamoxifen (Tam) plus Fluoxymesterone (Flu) 10 mg orally twice per day for 1 year
Number of subjects: 541
Study: 12654164

Group type: EXPERIMENTAL
Intervention: Isolated isoflavone supplement (86 mg/d, derived from red clover)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10891022

Group type: EXPERIMENTAL
Intervention: WHO‐ORS
Number of subjects: 97

Group type: COMPARATOR
Intervention: C‐ORS
Number of subjects: 97
Study: 8648872

Group type: EXPERIMENTAL
Intervention: Hospice and advance directives
Number of subjects: 0
Study: 1418893

Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam
Number of subjects: 212

Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 212
Study: 6363740

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole and trimethoprim
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31049414

Group type: EXPERIMENTAL
Intervention: Enhanced care at public health facilities including clinical care guides, drugs for COPD, patient education flipcharts, staff training, and mobile phone follow-up.
Number of subjects: 313

Group type: COMPARATOR
Intervention: Standard care at public health facilities (control group).
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Comparison of intervention vs control.
Number of subjects: 313
Study: 30403674

Group type: EXPERIMENTAL
Intervention: Female garment workers experiencing IPV
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Worker's ability to mobilize resources in crises
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Savings beyond a threshold
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Ownership of jewellery/large household assets
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Moderately or highly controlling husband
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Substance abuse by husband
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Husband's involvement in extramarital sex
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Worker's education up to 6 years or more
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Education more than the husband
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Young age
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Having two or more children
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Experience of non-partner sexual violence
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: High acceptance of IPV
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Middle income group
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Household food insecurity
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Work at a factory in the Export Processing Zone
Number of subjects: 800
Study: 26672064

Group type: EXPERIMENTAL
Intervention: Peficitinib 50 mg
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: All peficitinib doses (25, 50, 100, 150 mg)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Peficitinib 25 mg
Number of subjects: 281
Study: 24704658

Group type: EXPERIMENTAL
Intervention: 1/f sound for 5 minutes and 33 seconds
Number of subjects: 26

Group type: COMPARATOR
Intervention: Simple resting for 5 minutes and 33 seconds (Control)
Number of subjects: 26
Study: 22198242

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 132
Study: 20185226

Group type: EXPERIMENTAL
Intervention: Monophasic levonorgestrel-ethinyl estradiol 150/30
Number of subjects: 314

Group type: COMPARATOR
Intervention: Triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30
Number of subjects: 314
Study: 17628451

Group type: EXPERIMENTAL
Intervention: LDE tablet of griseofulvin (125mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Immediate release conventional tablet of griseofulvin (125mg)
Number of subjects: 4
Study: 16209891

Group type: EXPERIMENTAL
Intervention: Paroxetine or Citalopram
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 60
Study: 14556131

Group type: EXPERIMENTAL
Intervention: Neostigmine 1 mg added to 3 mg/kg of 0.5% lidocaine (maximum 45 mL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No additives to the IVRA solution (Control group)
Number of subjects: 54
Study: 10364900

Group type: EXPERIMENTAL
Intervention: SASP 2000 (maximum 3000) mg daily (n = 68)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: MTX 7.5 (maximum 15) mg weekly (n = 69)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: SASP + MTX (n = 68)
Number of subjects: 205

Group type: COMPARATOR
Intervention: SASP (n = 68)
Number of subjects: 205

Group type: COMPARATOR
Intervention: MTX (n = 69)
Number of subjects: 205
Study: 9345416

Group type: EXPERIMENTAL
Intervention: High dose intravenous immunoglobulin (IVIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1999791

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 6434223

Group type: EXPERIMENTAL
Intervention: Epoprostenol infusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cold stimulation
Number of subjects: 26
Study: 31712247

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 0
Study: 28371942

Group type: EXPERIMENTAL
Intervention: Physical activity self-management and coaching intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Social interaction intervention
Number of subjects: 46
Study: 27221477

Group type: EXPERIMENTAL
Intervention: Modified natural cycle (n=118)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Artificial cycle with GnRH-agonist (n=118)
Number of subjects: 236
Study: 23937218

Group type: EXPERIMENTAL
Intervention: Two-target RSVP streams (T1 and T2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-target RSVP streams (T1, T2, and a third target)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Accurate reporting of T1 and T2
Number of subjects: 0
Study: 22189672

Group type: EXPERIMENTAL
Intervention: EGb 761® 120 mg twice daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: EGb 761® 240 mg once daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 20629597

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 100 microg daily for 4 weeks
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 17695691

Group type: EXPERIMENTAL
Intervention: PIKO-1 device
Number of subjects: 352

Group type: COMPARATOR
Intervention: Conventional spirometer
Number of subjects: 352
Study: 15855581

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 2532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2532
Study: 11795350

Group type: EXPERIMENTAL
Intervention: Raloxifene (selective estrogen receptor modulator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 0
Study: 9018407

Group type: EXPERIMENTAL
Intervention: Water‐Del (metered: 200 ml water every 15 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: ad libitum every 15 min (ad‐lib‐15)
Number of subjects: 10

Group type: COMPARATOR
Intervention: ad libitum (ad‐lib)
Number of subjects: 10
Study: 7943678

Group type: EXPERIMENTAL
Intervention: B-MAST questionnaire for detecting alcoholism
Number of subjects: 0
Study: 3086927

Group type: EXPERIMENTAL
Intervention: Motivational letter
Number of subjects: 277

Group type: COMPARATOR
Intervention: No motivational letter (Control)
Number of subjects: 277
Study: 30111304

Group type: EXPERIMENTAL
Intervention: Thermal ablation (Radiofrequency ablation (RFA) or Microwave ablation (MWA))
Number of subjects: 618

Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Thermal ablation (RFA or MWA)
Number of subjects: 618
Study: 24919587

Group type: EXPERIMENTAL
Intervention: Exercise program + phototherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise program + placebo phototherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise program
Number of subjects: 0
Study: 23123065

Group type: EXPERIMENTAL
Intervention: 2‐trimethylammonium ethyl methacrylate chloride (T) and sulfobetaine methacrylate (S) coatings at 30% or 35% concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3‐hydroxypropyl methacrylate (HP) coating at 30% concentration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated specimens)
Number of subjects: 0
Study: 21551508

Group type: EXPERIMENTAL
Intervention: DAS 0‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAS TJC53
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAS TJC44
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DAS, DAS alternative and DAS28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient percentages with joint damage progression
Number of subjects: 0
Study: 18296460

Group type: EXPERIMENTAL
Intervention: Antioxidants (selenium 10 mug, zinc 5 mg, vitamin A 0.9 mg, vitamin E 100 mg, vitamin C 50 mg)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Folinic acid (0.1 mg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Antioxidants
Number of subjects: 156

Group type: COMPARATOR
Intervention: Folinic acid
Number of subjects: 156

Group type: COMPARATOR
Intervention: Biochemical outcomes
Number of subjects: 156
Study: 16516782

Group type: EXPERIMENTAL
Intervention: Hansatome microkeratome with zero compression heads (160 microm, 180 microm, 200 microm)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Hansatome microkeratome with zero compression heads
Number of subjects: 153
Study: 12709801

Group type: EXPERIMENTAL
Intervention: Faropenem daloxate (300 mg, twice daily for 7 days)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg, twice daily for 7 days)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Faropenem daloxate
Number of subjects: 452

Group type: COMPARATOR
Intervention: Cefuroxime axetil
Number of subjects: 452
Study: 10618328

Group type: EXPERIMENTAL
Intervention: 20 minutes of slow exercise at 2.7 km/h
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Symptom limited graded exercise for a mean of 7.4 minutes
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Three minutes of symptom limited fast exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: No warm up exercise
Number of subjects: 18
Study: 9112443

Group type: EXPERIMENTAL
Intervention: Pion therapy (33-34.5 Gy pi)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional photon irradiation (60 Gy)
Number of subjects: 84
Study: 1287620

Group type: EXPERIMENTAL
Intervention: Cefaclor AF 500 mg once daily (at night)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Cefaclor 250 mg three times a day
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Cefaclor AF 375 mg twice daily
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Cefaclor AF (375 mg and 500 mg)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Cefaclor AF and Cefaclor
Number of subjects: 189
Study: 6961477

Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 in viscous gel
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo gel
Number of subjects: 7
Study: 30004247

Group type: EXPERIMENTAL
Intervention: Intervention (training, written menu feedback, printed resources)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study: 29874271

Group type: EXPERIMENTAL
Intervention: Fluid balance-adjusted creatinine at CVVH initiation
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Bicarbonate levels
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Unadjusted creatinine
Number of subjects: 107
Study: 26272450

Group type: EXPERIMENTAL
Intervention: 60 mg oral fimasartan (FMS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 30 mg intravenous (IV) fimasartan (FMS)
Number of subjects: 16
Study: 24629631

Group type: EXPERIMENTAL
Intervention: Topiramate (200mg/day) plus CBT
Number of subjects: 74

Group type: COMPARATOR
Intervention: CBT only
Number of subjects: 74
Study: 23027677

Group type: EXPERIMENTAL
Intervention: Acute 1-mg dose of alprazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18245061

Group type: EXPERIMENTAL
Intervention: Multimedia consent procedure
Number of subjects: 188

Group type: COMPARATOR
Intervention: Routine consent condition (control)
Number of subjects: 188
Study: 17158250

Group type: EXPERIMENTAL
Intervention: Nasal CPAP (8 cmH(2)O) for 6 h
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (nasal mask without CPAP)
Number of subjects: 24
Study: 16827766

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15000549

Group type: EXPERIMENTAL
Intervention: Turning relative to the room (updated environment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Turning relative to the campus (nonupdated environment)
Number of subjects: 0
Study: 10210759

Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of meta-analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limitations of meta-analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate effect of treatments
Number of subjects: 0
Study: 8896514

Group type: EXPERIMENTAL
Intervention: B‐C7 (anti‐TNF monoclonal antibody)
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study: 1812905

Group type: EXPERIMENTAL
Intervention: Thermal debonding device
Number of subjects: 15

Group type: COMPARATOR
Intervention: Mechanical pliers
Number of subjects: 15
Study: 6684468

Group type: EXPERIMENTAL
Intervention: 600 mg X day‐1 for 5 consecutive days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1g X day‐1 for 5 consecutive days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for 5 consecutive days
Number of subjects: 12
Study: 29883839

Group type: COMPARATOR
Intervention: Medical history of asthma or eczema (Control group)
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Children not carrying the IL13-rs20541 variant allele
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Children carrying the IL10 triple variant haplotype
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Candidate polymorphisms in IL4 and IL4R
Number of subjects: 876
Study: 28210808

Group type: EXPERIMENTAL
Intervention: Albuterol (5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levalbuterol (2.5 mg)
Number of subjects: 24
Study: 25907813

Group type: EXPERIMENTAL
Intervention: Structured exercise intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Structured health education control group
Number of subjects: 135
Study: 22936524

Group type: EXPERIMENTAL
Intervention: PDA, daily tailored feedback messages (PDA + FB)
Number of subjects: 210

Group type: COMPARATOR
Intervention: PDA, no-daily feedback
Number of subjects: 210

Group type: COMPARATOR
Intervention: paper diary (PD), no-daily feedback
Number of subjects: 210
Study: 21976939

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 80 mg orally, twice a day for four weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo, twice a day for four weeks
Number of subjects: 30
Study: 18502591

Group type: EXPERIMENTAL
Intervention: Naltrexone with BASICS counseling
Number of subjects: 14
Study: 15875189

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin 100 IU day(‐1), 1,000 mg day(‐1) elemental calcium, 400 IU day(‐1) vitamin D
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (1,000 mg day(‐1) elemental calcium, 400 IU day(‐1) vitamin D)
Number of subjects: 78
Study: 12509592

Group type: EXPERIMENTAL
Intervention: FOK plus ImPACT
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: FOK plus ImPACT plus boosters
Number of subjects: 817

Group type: COMPARATOR
Intervention: FOK only
Number of subjects: 817

Group type: COMPARATOR
Intervention: FOK without boosters
Number of subjects: 817
Study: 10759092

Group type: EXPERIMENTAL
Intervention: Combination therapy with ribavirin and interferon alfa-2b
Number of subjects: 345

Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 345
Study: 9017757

Group type: EXPERIMENTAL
Intervention: Rate of digit presentation (slow vs fast)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delay between stimulus presentation and estimations of time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive tasks (arithmetic and recall)
Number of subjects: 0
Study: 2001021

Group type: EXPERIMENTAL
Intervention: Desflurane at 6, 9, and 12% (0.83, 1.24, and 1.66 MAC) in O2 alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Desflurane at 3, 6, and 9% in O2 with 60% N2O
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Desflurane at 0.83 and 1.66 MAC after 6 h exposure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypercapnia secondary to spontaneous ventilation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rhythmic, loud clapping at 1.24 MAC
Number of subjects: 12
Study: 6342542

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.2 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31636243

Group type: EXPERIMENTAL
Intervention: 1 µg/kg dexmedetomidine plus local infiltration of 0.2 ml/kg bupivacaine 0.5% (BD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine and normal saline (BO)
Number of subjects: 60
Study: 30298411

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) - two placebo tablets twice daily for 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 40
Study: 29219945

Group type: EXPERIMENTAL
Intervention: VATS plication of the diaphragm
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bilateral simultaneous VATS plication
Number of subjects: 35
Study: 25044768

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (non-diabetic subjects, n=31)
Number of subjects: 38
Study: 24386911

Group type: EXPERIMENTAL
Intervention: BD + HDM/SCT
Number of subjects: 56

Group type: COMPARATOR
Intervention: HDM/SCT alone
Number of subjects: 56
Study: 22839300

Group type: EXPERIMENTAL
Intervention: Interactive nutrition CD and parenting DVD, along with instructions for optimal resource utilization.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Generic nutrition and physical activity brochure and a physical activity resource to blind participants to group allocation.
Number of subjects: 150
Study: 19686477

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (1.5 ml) with fentanyl (0.3 ml, 15 microg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (1.5 ml) with fentanyl (0.3 ml, 15 microg)
Number of subjects: 80
Study: 17452505

Group type: EXPERIMENTAL
Intervention: Trandolapril (4 mg per day)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 15054428

Group type: EXPERIMENTAL
Intervention: 750 mg vitamin C
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 7500 mg vitamin C
Number of subjects: 6
Study: 11694610

Group type: COMPARATOR
Intervention: Nutrition counseling training for doctors (20 hours)
Number of subjects: 429
Study: 9392913

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (no corticosteroids)
Number of subjects: 129
Study: 7910089

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine with 69‐kd membrane protein (CP4)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine without 69‐kd membrane protein (CP5)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine combined with diphtheria and tetanus toxoids (CP4DT or CP5DT)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (CP5DT) for 4‐ to 6‐year‐old children
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 159
Study: 3309829

Group type: EXPERIMENTAL
Intervention: 1 g cefotiam pre-operative antibioprophylaxis
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no cefotiam)
Number of subjects: 115